M. G. Rybalkina

M. G. Rybalkina

Auto-generated profile, based on publicly available information

M. G. Rybalkina

The Orenburg State Medical Academy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2025 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
AVAnna Voronkova
Anna Voronkova
EZElena Zhekaite
Elena Zhekaite
IFI. R. Fatkhullina
I. R. Fatkhullina
OGO. I. Golubtsova
O. I. Golubtsova
EEE. A. Enina
E. A. Enina
EKElena Kondatyeva
Elena Kondatyeva
In the Russian Federation, patients with cystic fibrosis (CF) under 19 years of age receive targeted therapy with two drugs: lumacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor. Currently, a large volume of information has accumulated regarding possible adverse drug reactions (ADRs) during long-term targeted therapy in children with CF.   The aim of the study was to investigate the ADR profile associated with long-term use of CFTR modulators in children with CF.   Methods. Data on the targeted therapy were taken from the Russian registry of CF patients (2021 – 2024). The data of 392 patients at the start of therapy with lumacaftor/ivacaftor, 196 patients after 1 year, and 36 patients after 2 years were analyzed. The data of 220 patients at the start of therapy with elexacaftor/tezacaftor/ivacaftor, 214 patients after 1 year, and 43 patients after 2 years were analyzed. Early adverse reactions were assessed within 30 days from the start of therapy. Change in the adverse reaction profile was assessed after 360 and 720 days.   Results. The number of adverse reactions in patients receiving lumacaftor/ivacaftor was 51.27 % for 1 month. It decreased more than 2-fold (20.4 %) by the end of the 1st year (p1–2 < 0.001) due to a decrease in the number of patients with cough, shortness of breath, elevated alanine aminotransferase (ALT) / aspartate aminotransferase (AST) levels, and diarrhea. After 2 years, the incidence of adverse reactions was 55.5 % (p2–3 < 0.001), the number of patients with subfebrile body temperature/fever increased (p2–3 < 0.001; p1–3 < 0.001), the rate of fatigue increased to 11.1 % (p2–3 = 0.029), and the rate of sleep disturbance increased (from 0.25% at the start to 11.1 % after 2 years of therapy; p1–3 < 0.001; p2–3 < 0.001). The average incidence of adverse reactions per patient was 2.27 ± 0.45 for lumacaftor/ivacaftor. The total incidence of ADRs with elexacaftor/tezacaftor/ivacaftor combination therapy was 48.2 % at the start, 19.6 % after 1 year (p1–2 < 0.001), and increased to 41.9 % after 2 years (p2–3 < 0.001) due to subfebrile body temperature/fever – from 1.9 to 6.9 % (p1–3 = 0.032), headache – from 2.3 to 11.6 % (p1–3 = 0.003), and fatigue – up to 13.9 % (p1–3 < 0.001; p2–3 = 0.002). The average incidence of ADRs per patient was 2.56 ± 0.71 with elexacaftor/tezacaftor/ivacaftor combination therapy. More ADRs were observed at the start of therapy with lumacaftor/ivacaftor compared to elexacaftor/tezacaftor/ivacaftor (p = 0.019). The frequency of elevated ALT/AST levels at the start of therapy with lumacaftor/ivacaftor was higher than for elexacaftor/tezacaftor/ivacaftor (p = 0.02). Rash was observed more often at the start of therapy with elexacaftor/tezacaftor/ivacaftor (p < 0.001), fatigue – at the start of lumacaftor/ivacaftor (p = 0.011). No difference in the ADR profile was found after 2 years of therapy.   Conclusion. A higher number of ADRs was associated with lumacaftor/ivacaftor compared to elexacaftor/tezacaftor/ivacaftor. Over time, the main adverse drug reactions associated with respiratory and gastrointestinal symptoms resolve, but the number of patients complaining of fatigue, sleep disturbances, headaches, subfebrile temperature and fever increases, requiring active follow-up and adjustment of the therapy if necessary.

21 September 2026 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
EKElena Kondatyeva
Elena Kondatyeva
AVAnna Voronkova
Anna Voronkova
EZElena Zhekaite
Elena Zhekaite
VKV. N. Kovalev
V. N. Kovalev
AOA. V. Orlov
A. V. Orlov
МРМ. Г. Рыбалкина
М. Г. Рыбалкина
Introduction. Prior to recent years, treatment of cystic fibrosis (CF) consisted primarily of symptom management. The pathogenetic therapy with CFTR modulators has emerged as a revolutionary method, supplying the capacity to correct the underlying CFTR chloride channel dysfunction. Aim. To evaluate the efficacy of the generic ivacaftor/tezacaftor/elexacaftor and ivacaftor Trileksa® in a group of patients with pediatric cystic fibrosis, who have been previously treated with branded CFTR modulator Trikafta®, over a 9-month period. Materials and methods. The Russian Cystic Fibrosis Patient Registry (RCFPR) data were analysed. A total of 156 subjects (82 girls (52.6%) and 74 boys (47.4%) aged 6 to 17 years) with a median age at treatment initiation Me (Q1; Q3) 12 (10; 14) were included in the study. Before starting the generic drug, all children received the brand-name drug. The median duration of treatment with the original drug was 25 (19; 30) months. Results. The median sweat test value achieved during treatment with the brand-name drug remained at the cutoff level of 64 (56; 81) mmol/L after 9 months of treatment with the generic drug (p1-4 = 0.93). The median FEV1 and FVC (%pred spirometry measurements) remained stable without negative changes overtime (FEV1 p1-4 = 0.40, FVC p1-4 = 0.70). The patients had significant changes in weight and height over the 9-month course of treatment. Adverse reactions to Trilexa therapy were rare, and the incidence was comparable with that observed for the generic drug. A slight increase in total bilirubin within reference ranges from 9.6 (7.4; 15.4) at baseline to 11.9 (8.9; 17.5) after 9 months was reported (p = 0.02) while the frequency of elevated liver function tests decreased from 5.2% to 3.2%. The number of patients with mental disorders increased: no depressive coditions were observed at treatment initiation, but after 9 months they were reported in 3.2% of patients. The percentage of patients with sleep disturbances increased from 1.3 to 3.8%, headaches from 3.8 to 6.4%, and fatigue from 4.7 to 6.4%. Conclusions. The generic Trileksa is not inferior to the brand-name drug, helps stabilize the achieved clinical and therapeutic outcomes and leads to further improvement in the course of the disease. It is safe, and well tolerated in patients. The long-term efficacy and safety of the drug must be monitored and continuously evaluated while on the market.

1 June 2019 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
EKE. Kondratyeva
E. Kondratyeva
EFE. Furman
E. Furman
VSV. Shadrina
V. Shadrina
ACA. Chernyak
A. Chernyak
EAEvgeniya Amelina
Evgeniya Amelina
VYV. Yakovleva
V. Yakovleva

1 June 2016 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
PDF file
EAElena Amelina
Elena Amelina
SKS. Krasovsky
S. Krasovsky
АCАlexander Cherniak
Аlexander Cherniak
NKNataliya Kashirskaya
Nataliya Kashirskaya
EKE. Kondratieva
E. Kondratieva
EVE. Vodovozova
E. Vodovozova
Objectives: The establishment of cystic fibrosis (CF) databases allows caregivers to compare different approaches and improve CF care. The longitudinal data allows the understanding of trends in CF clinical course. We present the 9 years data of the Israeli CF Patient Registry. Methods: Epidemiological, genetic and clinical data from all CF patients were entered into database registry during the years 2005-13. Results: 529 patients were followed in 2013, 58% of them adults (>18 yrs), compared to 498 in 2005, 47% adults (p = 0.048). Median FEV 1 improved from 79% predicted in 2008 to 82.5% predicted in 2013 (p = 0.015). Despite the improved outcome the prevalence of CF decreased from 1:14,000 in 2005 to 1:15,370 in 2013 (p = 0.004), probably due to less CF births. The median age at diagnosis was 0.7 y (0-65 y), meconium ileus was the presenting symptom in 14%. W1282X and delF508 were the most common CFTR mutations (23% each). Chronic growth of P. aeruginosa in sputum was observed in 40% of patients compared to 32% in 2005 (p = 0.043). Staphylococcal colonization increased from 14% to 34% in these years (p < 0.05). Median BMI-SDS in CF children was-0.1. CF adults had median BMI of 22.5 (females 20.8, males 22.9) compared to 21.2 in 2007 (p < 0.05). CF related diabetes was reported in 11% in 2005 and 19% in 2013 (p = 0.001). Conclusions: CF patients in 2013 are older and having better lung function and nutritional status, possibly due to improved care but with higher prevalence of bacterial colonization.

14 October 2026 in Journal of Respiratory Medicine
Verified
Journal Article
Closed access
VSV.V. Shadrina
V.V. Shadrina
ASAlexander Sorokin
Alexander Sorokin
OKO.V. Kondratenko
O.V. Kondratenko
EVE.A. Vasilyeva
E.A. Vasilyeva
MRM.G. Rybalkina
M.G. Rybalkina
EKE.I. Kondratieva
E.I. Kondratieva
Cystic fibrosis (CF) is a severe hereditary disease that leads to decreased lung function. Objective. To assess the dynamics of lung function changes in CF patients living in the Volga Federal District (VFD) regions based on data from the 2017 and 2023 registries. Material and methods. Spirometry data from 375 patients from the 2017 CF patient registry and 451 patients from the 2023 registry were analyzed. Results. The median FEV1 data in VFD patients was 76.8% of the predicted value in 2017 and significantly increased to 95.3% of the predicted value in 2018. in 2023 (p<0.001). In 2017, FEV1 values in patients with CF in the Volga Federal District were not significantly different from those in the Russian Federation (75.5% of the predicted value), while in 2023, they were significantly higher than in patients in other regions of Russia (81.1% of the predicted value), p<0.001. FEV1 values increased significantly in patients from the Nizhny Novgorod Region, Orenburg Region, Perm Krai, the Republic of Tatarstan, and the Chuvash Republic. The median FVC in patients with CF from the Volga Federal District in 2017 was 85.1% of the predicted value and significantly increased to 94.0% of the predicted value in 2023 (p<0.01). In 2017, the FVC indicators in patients with CF in the Volga Federal District did not differ significantly from those in patients in the Russian Federation (86.0% of the predicted value), and in 2023 they were significantly higher than in patients in other regions of Russia (91.0% of the predicted value), p=0.037. The FVC indicators in 2023, compared with 2017, significantly increased in patients in the Nizhny Novgorod Region (p<0.001), Orenburg Region (p<0.001), Perm Krai (p=0.021), the Republic of Tatarstan (p=0.043), and the Chuvash Republic (p=0.003). In patients in the Samara Region, the indicators remained stable (p=0.331). Conclusions. FEV1 and FVC values in CF patients in both the Volga Federal District and the Russian Federation increased significantly in 2023 compared to 2017. Patient data from Volga Federal District regions where specialized CF centers were established were more informative, and patients had higher lung function values.

27 September 2024 in Gylym Alliansy
Verified
Journal Article
Closed access
AAA.V. Abubakirova
A.V. Abubakirova
MSM.A. Skachkova
M.A. Skachkova
NTN.F. Tarasenko
N.F. Tarasenko
EKE.G. Karpova
E.G. Karpova
MRM.G. Rybalkina
M.G. Rybalkina
NPN.N. Puxovikova
N.N. Puxovikova
Cardiovascular diseases (CVD) remain the leading cause of mortality in both industrialized and developing countries, including Russia. Recent evidence suggests that atherosclerosis, a major precursor to CVD, begins in childhood and adolescence and progresses throughout life due to genetic and modifiable risk factors. This study focuses on new screening methods for early diagnosis of cardiovascular pathology. Purpose: to assess the functional state of the cardiovascular system and adaptive reserves of children and adolescents in the Orenburg region. Methods. The study included 518 children aged 6 to 18 years from urban and rural areas in Orenburg and the Orenburg region. The adaptive capacity and stress levels of their regulatory systems were measured using the “Varikard-Express” software complex (Russia). Additionally, the functional state of the cardiovascular system was evaluated through the “Cardiovisor-06s” computer heart screening system (Russia), which provides 3D heart visualizations (“heart portraits”). Results. Findings revealed significant adaptation disorders, including pronounced stress and disruption of the adaptation process, which were more prevalent among urban residents compared to rural residents (60.57% vs. 39.42%). Age-based analysis indicated that children aged 10-14 exhibited the highest rates of adaptation disorders, with 52.34% experiencing pronounced or sharply pronounced stress of the regulatory system compared to other age groups (p < 0.05). Conclusion. The study identified prevalent deviations in cardiovascular function and adaptive capacity among children and adolescents. More than half of the participants demonstrated varying levels of cardiovascular dysfunction, and over one-third had disruptions in adaptive processes. These findings underscore the importance of early screening for cardiovascular and adaptation-related issues in youth to facilitate timely interventions. Keywords: cardiovascular system, children, physical development, screening evaluation